1. Home
  2. FSM vs SYRE Comparison

FSM vs SYRE Comparison

Compare FSM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSM

Fortuna Silver Mines Inc (Canada)

HOLD

Current Price

$9.46

Market Cap

2.6B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$47.25

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSM
SYRE
Founded
1990
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
FSM
SYRE
Price
$9.46
$47.25
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$14.00
$60.13
AVG Volume (30 Days)
6.3M
671.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$35.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$10.91
52 Week High
$13.85
$49.31

Technical Indicators

Market Signals
Indicator
FSM
SYRE
Relative Strength Index (RSI) 40.07 67.53
Support Level $7.77 $15.01
Resistance Level $10.16 N/A
Average True Range (ATR) 0.50 2.24
MACD -0.15 0.30
Stochastic Oscillator 29.31 78.80

Price Performance

Historical Comparison
FSM
SYRE

About FSM Fortuna Silver Mines Inc (Canada)

Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: